Development of an immunoassay for differentiating human immunodeficiency virus infections - from vaccine-induced immune response in Tiantan vaccine trials in China

Clinical Biochemistry

Volumn 45, Issue 15, 2012, Pages 1219-1224

  Yuan, Zuowei ^a   Chen, Weixian ^a   Zhang, Juan ^a   Zhang, Jun ^b   Xiang, Tingxiu ^a   Hu, Jieli ^a   Wu, Zhijuan ^a   Du, Xi ^a   Huang, Ailong ^a   Zheng, Jian ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Artron BioResearch Inc   (Canada)

Author keywords

Differential diagnosis; HIV infections; HIV vaccine; Rapid Flow through Test

Indexed keywords

GLYCOPROTEIN GP 36; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEIN SK1; PROTEIN SK2; PROTEIN SK3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CHINA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROLOGY;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; CLINICAL TRIALS, PHASE I AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FALSE POSITIVE REACTIONS; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; IMMUNOASSAY; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; VACCINATION; VACCINES, ATTENUATED;

EID: 84866282883     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.05.013     Document Type: Article

References (26)

1. Vitoria M., Granich R., Gilks C.F., et al. The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol 2009, 131:844-848.
2. Ghys P.D., Walker N., McFarland W., et al. Improved data, methods and tools for the 2007 HIV and AIDS estimates and projections. Sex Transm Infect 2008, 84(Suppl. 1):1-4.
3. Berwick D. "We all have AIDS": case for reducing the cost of HIV drugs to zero. BMJ 2002, 324:214-216.
4. Esparza J. An HIV vaccine: how and when?. Bull World Health Organ 2001, 79:1133-1137.
5. Hanke T., McMichael A.J., Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 2007, 88:1-12.
6. Huang X., Xu J., Qiu C., et al. Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses. Vaccine 2007, 25:2620-2629.
7. Teng T., Shao Y. Scientific approaches to AIDS prevention and control in China. Adv Dent Res 2011, 23:10-12.
8. Shao Y., Li T., Wolf H., et al. The safety and immunogenicity of HIV-1 vaccines based on the DNA and replication competent vaccinia vector in phase I clinical trial [Abstract]. Retrovirology 2009, 6(Suppl. 3):P404.
9. Khurana S., Needham J., Mathieson B., et al. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. J Virol 2006, 80:2092-2099.
10. Khurana S., Needham J., Park S., et al. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. J Acquir Immune Defic Syndr 2006, 43:304-312.
11. Khurana S., Norris P.J., Busch M.P., et al. HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection. J Clin Microbiol 2010, 48:281-285.
12. Ravanshad M., Sabahi F., Mahboudi F., et al. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens. Saudi Med J 2006, 27:31-36.
13. Rosa D.S., Ribeiro S.P., Almeida R.R., et al. A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses. PLoS One 2011, 6:e16921.
14. Duerr A., Wasserheit J.N., Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 2006, 43:500-511.
15. Whitney J.B., Ruprecht R.M. Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 2004, 17:17-26.
16. Gamble L.J., Matthews Q.L. Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther 2010, 5:9-26.
17. Nabel G.J. HIV vaccine strategies. Vaccine 2002, 20:1945-1947.
18. Spearman P. HIV vaccine development: lessons from the past and promise for the future. Curr HIV Res 2003, 1:101-120.
19. Amanna I.J., Slifka M.K. Wanted, dead or alive: new viral vaccines. Antiviral Res 2009, 84:119-130.
20. Patterson L.J., Robert-Guroff M. Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther 2008, 8:1347-1363.
21. Koff W.C., Parks C.L., Berkhout B., et al. Replicating viral vectors as HIV vaccines summary report from IAVI Sponsored Satellite Symposium, International AIDS Society Conference, July 22, 2007. Biologicals 2008, 36:277-286.
22. Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 2007, 18:546-556.
23. Overbaugh J., Morris L. The antibody response against HIV-1. Cold Spring Harb Perspect Med 2012, 2:a007039.
24. Schmidt B.L. Detection of HIV infection by serologic procedures. Z Hautkr 1990, 65(633-4):637-639.
25. Marcelino J.M., Barroso H., Gonçalves F., et al. Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins. J Clin Microbiol 2006, 44:607-611.
26. Aidoo S., Ampofo W.K., Brandful J.A., et al. Suitability of a rapid immunochromatographic test for detection of antibodies to human immunodeficiency virus in Ghana, West Africa. J Clin Microbiol 2001, 39:2572-2575.